On October 13, the Hubei Medical Insurance Platform issued the "Notice on Improving Medical Consumables Sunshine Procurement and Dynamic Adjustment Work" (hereinafter referred to as the "Notice"). This notice takes effect from October 15, 2025.

According to the notice, the main content includes procurement scope, application requirements, dynamic price adjustment of listed products, suspension and cancellation of listings, distribution and settlement, and supervision management.

**01 Procurement Scope**

Products that have obtained medical consumables C-codes or in vitro diagnostic reagent CJ-codes, comply with relevant regulations such as the "Medical Device Supervision and Administration Regulations," "Medical Device Registration and Filing Management Measures," and "In Vitro Diagnostic Reagent Registration and Filing Management Measures," and have obtained National Medical Insurance Medical Consumables Classification and Codes (27-digit C-codes for medical consumables, 22-digit CJ-codes for in vitro diagnostic reagents).

For in vitro diagnostic reagents used for blood source screening that have obtained drug approval numbers and national medical insurance drug classification and codes, in vitro diagnostic reagents labeled with radioactive nuclides, and drug-device combination products, these are included in the provincial procurement management subsystem's drug procurement management scope.

Medical consumables outside the procurement scope shall be temporarily procured independently by public medical institutions according to relevant regulations and filed with local county-level or higher medical insurance departments. Specific measures will be announced separately.

**02 Application Requirements**

Companies applying for sunshine procurement of products in the provincial procurement management subsystem must obtain medical insurance codes from the National Medical Insurance Information Business Coding Standard Database in advance, register accounts on the National Medical Insurance Service Platform or provincial procurement management subsystem in advance, submit written integrity commitments according to pharmaceutical price and tender procurement credit evaluation system requirements, commit to authorizing inquiries into relevant VAT invoice information when suspected of commercial bribery, monopolistic price increases, or tax-related violations, and submit relevant qualifications, product information, and the lowest listing (winning bid) prices on other national provincial procurement platforms (excluding volume-based procurement selected execution prices).

Products that have obtained 27-digit national medical insurance medical consumables codes must also apply through the national joint review portal in advance, with quoted prices not exceeding the lowest listing prices on other national provincial centralized procurement platforms, verified by other provinces, or submit screenshots of all listing (winning bid) prices on other national provincial procurement platforms as required.

Products with 22-digit national medical insurance medical consumables codes for in vitro diagnostic reagents must submit screenshots of all listing (winning bid) prices on other national provincial procurement platforms.

For products without listing prices on other provincial platforms, applicant companies must submit cost investigation reports from qualified third-party institutions or explanations of product price composition, innovation, and economic efficiency based on the principle of matching product performance with prices, considering reasonable price comparison relationships with products of the same category and similar functional attributes.

Innovative products that meet national and provincial requirements for supporting biomedical industry innovation development and products needed for public health events can open green channels and implement enterprise commitment-based application listings. Companies committing that application listing prices do not exceed the lowest listing prices on other provincial procurement platforms can receive priority review.

Applicant companies shall be responsible for the legality, authenticity, validity, accuracy, and completeness of materials provided. Applications without product price information will not be accepted.

**03 Dynamic Adjustment**

Price linkage occurs when new provincial low prices appear, with updates within 30 days. Listed medical consumables product prices should be linked to the lowest prices on other national provincial procurement platforms, with enterprises encouraged to actively reduce prices.

When listed products show new prices lower than provincial platform prices on other provincial procurement platforms, enterprises should maintain new lowest prices in the provincial system within 30 days of the new lowest price execution and upload price change related materials.

**04 Suspension and Cancellation**

Products meeting certain criteria will be suspended from listing, including those requesting suspension due to production halt, failure to report or maintain listing information as required, failure to link to lower prices on other platforms, being subjected to regulatory control measures, and other circumstances.

Suspended products generally cannot be restored within one year. Products with no transaction records for two years or more are automatically listed in the alternative catalog with suspended transactions.

Products will be canceled from listing for reasons including production cessation, license cancellation or revocation, no longer being sold in China, remaining suspended for one year or more, remaining in alternative catalog for one year or more without restoration, and other circumstances.

**05 Distribution and Settlement**

Production enterprises are the primary responsible parties for supply guarantee and can distribute independently or select capable distribution enterprises. Emergency medical consumables must be delivered within 4 hours (extended to 6 hours for remote areas), while general medical consumables must be delivered within 24 hours, not exceeding 48 hours maximum.

Medical institutions should select procurement varieties from the listed catalog according to clinical needs, sign purchase contracts with listed enterprises promptly, and settle payments according to contract agreements.

**06 Supervision and Management**

Public medical institutions can directly use listing ceiling prices as procurement prices or negotiate independently with production enterprises through the provincial system's negotiation module. Various levels of medical insurance departments should strengthen supervision of enterprises in application, price linkage, risk management, and supply distribution processes.

The provincial pharmaceutical centralized procurement institution should conduct medical consumables procurement governance work according to national and provincial requirements, strengthen monitoring and statistical analysis of listing prices, procurement, and distribution conditions, and regularly provide feedback to the provincial medical insurance bureau.

Note: The above content is for reference only and does not constitute investment advice. Interpretations of official policies in this article represent only platform viewpoints, with official documents as the standard.